Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 73Breast Neoplasms 70Colorectal Neoplasms 39Prostatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 25Stomach Neoplasms 20Carcinoma, Hepatocellular 20Uterine Cervical Neoplasms 19Pancreatic Neoplasms 15Anxiety Disorders 15Leukemia, Myeloid, Acute 14Hematologic Neoplasms 13Colonic Neoplasms 13Brain Neoplasms 13Urinary Bladder Neoplasms 12Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Head and Neck Neoplasms 11Esophageal Neoplasms 10Diabetes Mellitus 10Ovarian Neoplasms 9Melanoma 9Liver Neoplasms 9Sarcoma 8Rectal Neoplasms 8Pulmonary Disease, Chronic Obstructive 8Multiple Myeloma 8Esophageal Squamous Cell Carcinoma 8Disease 8

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × TNBC × Clear all
NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡